Dynamic Technology Lab Private Ltd Purchases New Stake in ANI Pharmaceuticals, Inc. $ANIP

Dynamic Technology Lab Private Ltd purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, Holdings Channel reports. The fund purchased 3,203 shares of the specialty pharmaceutical company’s stock, valued at approximately $209,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Aberdeen Group plc raised its position in shares of ANI Pharmaceuticals by 76.1% in the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock valued at $28,059,000 after purchasing an additional 181,134 shares during the period. Woodline Partners LP acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at about $11,144,000. Teacher Retirement System of Texas raised its holdings in ANI Pharmaceuticals by 3,156.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company’s stock valued at $9,617,000 after acquiring an additional 142,854 shares during the period. Global Alpha Capital Management Ltd. lifted its position in ANI Pharmaceuticals by 17.2% during the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after acquiring an additional 126,500 shares during the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new stake in ANI Pharmaceuticals during the first quarter worth approximately $7,030,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $84.36 on Thursday. The firm has a market cap of $1.90 billion, a PE ratio of -109.56 and a beta of 0.54. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The stock’s fifty day moving average price is $90.18 and its two-hundred day moving average price is $78.77. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same period in the prior year, the firm posted $1.34 EPS. ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Activity

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $98.04, for a total transaction of $98,040.00. Following the sale, the senior vice president owned 60,186 shares in the company, valued at approximately $5,900,635.44. This trade represents a 1.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $87.27, for a total transaction of $34,908.00. Following the completion of the transaction, the vice president directly owned 75,274 shares in the company, valued at $6,569,161.98. This trade represents a 0.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 32,871 shares of company stock valued at $2,963,993. Company insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Guggenheim upped their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. HC Wainwright increased their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $99.29.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.